종양과 신장 질환
Cancer-associated Kidney Disease
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
신장 질환과 암과의 관련성은 오래 전부터 다양한 형태로알려져 왔으나, 항암 약물 치료제의 발달, 조혈모세포 이식의 활성화, 다양한 표적 치료제의 개발로 암 환자에서의 신장 질환은 더욱 흔하고 복잡한 형태로 나타난다[1]. 특히 암환자의 생존율이 높아지면서, 암 치료 과정에서 신 손상을최소화하는 노력이 더욱 필요해지고 있다. 따라서 암 혹은암 치료의 합병증으로 발생하는 다양한 형태의 신장 질환에대한 정보와 이해가 필요하며, 이러한 이해를 바탕으로 암환자 치료에 신장내과 의사의 적극적인 참여가 필요한 시점이다[2,3]. 암 환자의 치료에서 발생하는 신장내과적 문제는표 1과 같으며, 본 논문에서는 암-신장학 분야의 최신 지견을5가지 부분으로 나누어 정리해 보고자 한다.
Abstract
Kidney disease is common in patients with cancer and includes diseases that occur in people without cancer. In addition, certain kidney disorders are related to either cancer therapy or the malignancy itself. Paraneoplastic glomerulonephritis and post-hematopoietic stem-cell transplantation kidney disease (thrombotic microangiopathy, veno-occlusive disease, and kidney injury from graft-versus-host disease) are prime examples. Newer cancer therapy has increased cancer cure rates and survival times, but nephrotoxicity remains an important complication of chemotherapy. Consequently, patients with cancer are at increased risk of developing acute kidney injury, chronic kidney disease, and fluid and electrolyte abnormalities. In patients with chronic kidney disease, therapeutic doses may need to be reduced. Therefore, it is essential that nephrologists be informed and involved in cancer care. Nephrologists must provide expertise in the evaluation and management of acute and chronic kidney disease, fluid and electrolyte disorders, and the use of various extracorporeal therapies in patients with cancer. Additionally, onco-nephrologists, who must be knowledgeable about the array of new chemotherapeutic agents and their potential effects on kidney function, are needed to provide integral care for patients with cancer.
참고문헌 (26)
- Salahudeen AK, "Onconephrology : the latest frontier in the war against kidney disease", J Am Soc Nephrol, 24, pp.26~30 (2013)
- Abudayyeh AA, "Onconephrology : the need and the emergence of a subspecialty in nephrology", Kidney Int, 85, pp.1002~1004 (2014)
- Berns JS, "Onco-nephrology : what the nephrologist needs to know about cancer and the kidney", Clin J Am Soc Nephrol, 7, pp.1691~ (2012)
- Salahudeen AK, "Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center", Clin J Am Soc Nephrol, 8, pp.347~354 (2013)
- Lam AQ, "Onco-nephrology : AKI in the cancer patient", Clin J Am Soc Nephrol, 7, pp.1692~1700 (2012)
- Rosner MH, "Onco-nephrology : the pathophysiology and treatment of malignancy-associated hypercalcemia", Clin J Am Soc Nephrol, 7, pp.1722~1729 (2012)
- Ganguli A, "Kidney diseases associated with haematological cancers", Nat Rev Nephrol, 11, pp.478~490 (2015)
- Wilson FP, "Onco-nephrology : tumor lysis syndrome", Clin J Am Soc Nephrol, 7, pp.1730~1739 (2012)
- Bosly A, "Rasburicase(recombinant urate oxidase)for the management of hyperuricemia in patients with cancer : report of an international compassionate use study", Cancer, 98, pp.1048~1054 (2003)
- Cambier JF, "Onco-nephrology : glomerular diseases with cancer", Clin J Am Soc Nephrol, 7, pp.1701~1712 (2012)
- Pani A, "Glomerular diseases and cancer : evaluation of underlying malignancy", J Nephrol, 29, pp.143~152 (2016)
- Kofman T, "Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders : a retrospective study of 18 cases", Medicine(Baltimore), 93, pp.350~358 (2014)
- Cho A, "Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy", Nephrol Dial Transplant, 26, pp.3496~3501 (2011)
- Porta C, "Renal effects of targeted anticancer therapies", Nat Rev Nephrol, 11, pp.354~370 (2015)
- Bridoux F, "Diagnosis of monoclonal gammopathy of renal significance", Kidney Int, 87, pp.698~711 (2015)
- Sethi S, "Spectrum of manifestations of monoclonal gammopathy-associated renal lesions", Curr Opin Nephrol Hypertens, 25, pp.127~137 (2016)
- Eom HS, "Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates : results of the Korean Multiple Myeloma Working Party(KMMWP)", Ann Hematol, 89, pp.489~497 (2010)
- Zannetti BA, "Bortezomib based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment", Am J Hematol, 90, pp.647~652 (2015)
- Ashutosh D Wechalekar, "Systemic amyloidosis", The Lancet, 387(10038), pp.2641~2654 (2016), Elsevier BV[DOI]
- Sethi S, "Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis", Kidney Int, 82, pp.226~234 (2012)
- Leung N, "How I treat amyloidosis : the importance of accurate diagnosis and amyloid typing", Blood, 120, pp.3206~3213 (2012)
- Sayed RH, "Natural history and outcome of light chain deposition disease", Blood, 126, pp.2805~2810 (2015)
- 김도희, "A case of Fanconi syndrome accompanied by crystal depositions in tubular cells in a patient with multiple myeloma", Kidney Research and Clinical Practice, 33(2), pp.112~115 (2014), 대한신장학회
- Yul Hee Cho, "De novo glomerulitis associated with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A single-center experience", Kidney Research and Clinical Practice, 32(3), pp.121~126 (2013), 대한신장학회
- Perazella MA, "Onco-nephrology : renal toxicities of chemotherapeutic agents", Clin J Am Soc Nephrol, 7, pp.1713~1721 (2012)
- Ha SH, "Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function", BMC Cancer, 14, pp.906~ (2014)